Company intelligence / Profile preview
Tango Therapeutics
Boston, Massachusetts, USAtangotx.com ↗
- Ownership
- Public · TNGX
- Development stage
- Other
01
Overview
TNG462 has shown durable clinical activity across multiple tumor types, including NSCLC and pancreatic cancer, in ongoing phase 1/2 clinical trials. Patients remain on treatment with a current median of 24 weeks. TNG456, a next-generation brain penetrant MTA-cooperative PRMT5 inhibitor, is entering phase 1/2 clinical trials in 1H 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Revolution Medicines (clinical collaboration for TNG462 in combination with RAS(ON) inhibitors)
04
Financials
- Market cap
- $3.5B
- Total revenue
- $62.4M
- Enterprise value
- $2.5B
Beyond the preview
Go deeper on Tango Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tango Therapeutics.